全文获取类型
收费全文 | 1078455篇 |
免费 | 84306篇 |
国内免费 | 2790篇 |
专业分类
耳鼻咽喉 | 15200篇 |
儿科学 | 30229篇 |
妇产科学 | 29258篇 |
基础医学 | 150856篇 |
口腔科学 | 29754篇 |
临床医学 | 97472篇 |
内科学 | 209692篇 |
皮肤病学 | 20079篇 |
神经病学 | 91803篇 |
特种医学 | 44564篇 |
外国民族医学 | 184篇 |
外科学 | 169965篇 |
综合类 | 27170篇 |
现状与发展 | 3篇 |
一般理论 | 437篇 |
预防医学 | 82500篇 |
眼科学 | 25662篇 |
药学 | 78917篇 |
1篇 | |
中国医学 | 1883篇 |
肿瘤学 | 59922篇 |
出版年
2021年 | 9878篇 |
2019年 | 9851篇 |
2018年 | 12884篇 |
2017年 | 9885篇 |
2016年 | 11067篇 |
2015年 | 12938篇 |
2014年 | 18745篇 |
2013年 | 27127篇 |
2012年 | 38439篇 |
2011年 | 40165篇 |
2010年 | 23142篇 |
2009年 | 21716篇 |
2008年 | 37226篇 |
2007年 | 39797篇 |
2006年 | 39348篇 |
2005年 | 38859篇 |
2004年 | 37473篇 |
2003年 | 35370篇 |
2002年 | 34030篇 |
2001年 | 37702篇 |
2000年 | 37931篇 |
1999年 | 32840篇 |
1998年 | 11808篇 |
1997年 | 10568篇 |
1996年 | 10217篇 |
1995年 | 9618篇 |
1994年 | 9112篇 |
1992年 | 27628篇 |
1991年 | 26975篇 |
1990年 | 26377篇 |
1989年 | 25391篇 |
1988年 | 23869篇 |
1987年 | 23477篇 |
1986年 | 22370篇 |
1985年 | 21763篇 |
1984年 | 17238篇 |
1983年 | 14753篇 |
1982年 | 9797篇 |
1981年 | 9092篇 |
1979年 | 17174篇 |
1978年 | 12631篇 |
1977年 | 10612篇 |
1976年 | 9745篇 |
1975年 | 10466篇 |
1974年 | 12941篇 |
1973年 | 12394篇 |
1972年 | 11720篇 |
1971年 | 10849篇 |
1970年 | 10341篇 |
1969年 | 10011篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
Michael Givel 《Int J Health Serv》2006,36(1):137-155
From the early 1980s to the present, neoliberal doctrine has called for government policies of privatization, funding cutbacks, and deregulation of public health and other domestic social programs in the belief that the market rather than the public sector can best organize and distribute crucial societal services. Proponents of a neoliberal and deregulatory mixed approach of command and control and self-regulation argue this approach provides the most adequate means to conduct regulation in the legalistic and adversarial U.S. regulatory process. In April 1994, the Occupational Safety and Health Administration issued a proposed rule to eliminate tobacco smoking in most workplace rooms, arguing secondhand tobacco smoke annually killed up to 13,700 nonsmokers. The tobacco industry purposely delayed public hearing procedures (later halted altogether by Congress and the president) primarily to advance unhindered private property rights and profits rather than submitting to a public command-and-control regulatory framework to reduce deaths due to secondhand tobacco smoke. 相似文献
42.
43.
Kevin L Taylor Rhonda K Oates Ron Grane Douglas W Leaman Ernest C Borden Daniel J Lindner 《Journal of interferon & cytokine research》2006,26(5):353-361
Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma. To investigate the ability of IFNs to inhibit angiosarcoma, we used two transformed murine endothelial cell lines that form angiosarcomas in vivo. SVR and MS1-VEGF cell lines express oncogenic H-ras or vascular endothelial growth factor (VEGF), respectively. IFN-alpha1,8, which is active against murine and human cells, inhibited SVR and MS1-VEGF proliferation in vitro by 40% at 10(3) U/mL (p = 0.028). In vivo, IFN-alpha1,8 inhibited SVR tumor volume by 71% (p = 0.047) and MS1-VEGF volume by 79% (p = 0.003). Tumor-induced angiogenesis was decreased in SVR tumors by 52% (p = 0.005) and in MS1-VEGF tumors by 58% (p = 0.001). Sera from IFN-alpha1,8-treated mice bearing either SVR or MS1-VEGF tumors demonstrated a 5-fold increase in IP-10/CXCL10 (p = 0.001), an IFN-induced antiangiogenic protein. Both recombinant IP-10 and IFN-alpha1,8 inhibited human umbilical vein endothelial cell (HUVEC) vessel formation in the fibrin gel assay, a three-dimensional culture model of angiogenesis, by 56% at 25 ng/mL and 50% at 1.2 ng/mL, respectively (p < 0.001). An IP-10 blocking antibody restored vessel formation to 80% of untreated controls (p = 0.001). Given the magnitude of the in vivo response, these data suggested that the antitumor effects of IFN-alpha1,8 were likely mediated through angiogenesis inhibition rather than solely by direct inhibition of tumor cell proliferation. 相似文献
44.
45.
Adriana B Campaner Alessandro Scapinelli Ruy O Machado Roberto E Dos Santos Geni W Beznos Tsutomu Aoki 《Gynecological endocrinology》2006,22(7):395-398
We report a case of a prepubertal girl with juvenile primary hypothyroidism presenting as ovarian cysts and precocious puberty. The 7-year-old female was referred to our clinic because of a pelvic/abdominal mass and vaginal bleeding. Besides these findings, on physical examination we noticed the thyroid gland globally increased and the presence of secondary sexual characteristics. Based upon the clinical profile and investigations, the patient was diagnosed with juvenile primary hypothyroidism due to autoimmune thyroiditis. The cysts and precocious puberty resolved spontaneously after the simple replacement of thyroid hormone. It is important to bear in mind hypothyroidism in cases of girls presenting ovarian cysts and precocious puberty in order to avoid unnecessary surgery on the ovaries. 相似文献
46.
Henk R Franke F Froukje Snaaijer Paul W H Houben Marius J van der Mooren 《Gynecological endocrinology》2006,22(12):692-697
OBJECTIVE: To assess the effects of adding combined estradiol/norethisterone acetate therapy (CENT) to goserelin acetate treatment (GA) of dysfunctional uterine bleeding (DUB) in perimenopausal women. METHODS: In a randomized, placebo-controlled, double-blind trial followed by an open follow-up study, 31 perimenopausal women with DUB were recruited from gynecological outpatient departments of two Dutch hospitals and randomized for treatment with either GA/placebo or GA/CENT for 6 months followed by 18 months of GA/CENT for all. The main outcome measures were abdominal pain, number of bleeding days, double-layer endometrial thickness (DET), Greene climacteric score (GCS), visual analog scale for well-being, bone mineral density (BMD) and mammographic density (BI-RAD score). RESULTS: Abdominal pain, number of bleeding days and DET decreased in both groups, the between-group difference in decrease not being statistically significant. GCS initially showed significant improvement in the GA/CENT group. BMD decreased significantly in the GA/placebo group (-4.1%) compared with the GA/CENT group (-0.3%). Another 18 months of GA/CENT did not result in a lasting difference in BMD between groups. BI-RAD scores did not differ significantly between or within the two groups. CONCLUSIONS: Adding CENT to GA treatment for DUB in perimenopausal women initially prevented BMD loss and improved climacteric complaints, while having no negative impact on vaginal bleeding, abdominal pain or BI-RAD scores. However, prolonged treatment did not result in a lasting prevention of bone loss. 相似文献
47.
Claudia Gedlicka Gudrun Hager Martina Weissenböck Wilhelm Gedlicka Birgit Knerer Johannes Kornfehl Michael Formanek 《Journal of oral pathology & medicine》2006,35(8):472-478
BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before. In SCC25, a SCC cell line isolated from tongue, growth inhibition but no overexpression of p21 was detected. The retinoblastoma gene, as a direct target of G1 cyclin-CDK complexes, showed an obvious shift from the hyperphosphorylated to the hypophosphorylated form under 1,25(OH)(2)Vitamin D(3), which indicates that the growth inhibition takes place in the G0/G1 phase. To explore the possible pathway of growth inhibition in SCC25 we investigated other cell cycle inhibitors (p18, p19, p27). METHODS: Synchronized cells were treated with 1,25(OH)(2)Vitamin D(3) over 96 h. The cell cycle status and expression of cell cycle-regulating proteins was determined by fluorescence-activated cell sorting (FACS) and Western blotting. An overexpression of p18 in 1,25(OH)(2)Vitamin D(3) vs. ethanol-treated cells was determined until 30 h in SCC25. No influence was detectable on the expression of p27 and p19. CONCLUSION: One mechanism by which 1,25(OH)(2)Vitamin D(3) controls cell growth might be the upregulation of p21. As p21 was unsusceptible to 1,25(OH)(2)Vitamin D(3) in SCC25, other inhibiting proteins were necessary to be tested. The proven upregulation of p18 seems to be the responsible step for growth inhibition of 1,25(OH)(2)Vitamin D(3) in SCC25. 相似文献
48.
49.
50.